natgillin/translations-raw huggingface dataset:
According to a further aspect of the present invention, a compositing is provided comprising a) pharmaceutically acceptable amount of an acetate salt of caspofungin; b) about 10-200 mg/ml of one or more pharmaceutically acceptable excipients effective to form a lyophilized cake; and c) a pharmaceutically effective amount of succinate providing a pharmaceutically acceptable pH. 
Smjesa prema bilo kojem od prethodnih zahtjeva, naznačeno time da ista obuhvaća: a) farmaceutski djelotvornu količinu acetatne soli kaspofungina; b) oko 10-200 mg/ml jedne ili više farmaceutski prihvatljive pomoćne tvari djelotvorne za tvorbu liofilizirane kolača; c) farmaceutski djelotvorna količina sukcinata djelotvorna za osiguranje farmaceutski prihvatljive PH vrijednosti.
The compound or pharmaceutically acceptable salt thereof for use of claim 12, wherein psoriasis is plaque-type psoriasis or refractory psoriasis. 
Spoj za uporabu prema zahtjevu 22, naznačen time da je psorijaza pločasta psorijaza ili refraktorna psorijaza.
The syringe of claim 1, further comprising a shoulder (220) formed on the recess (104) and configured for engaging a load bearing surface (220) of the piston. 
Å trcaljka prema zahtjevu 1, naznačena time da dodano sadrži obod (220) oblikovan na udubljenju (104) i konfiguriran za zahvaćanje nosive površine (220) klipa.
The submersible cleaning robot according to claim 1, wherein the front and rear second travel units have a smaller diameter than a diameter of the first travel units and a length of the front and rear second travel units in the left and right direction of the robot body is set to be longer than a length of the first travel units in the left and right direction of the robot body. 
Podvodni robot za čišćenje (1) prema zahtjevu 1, naznačen time da je duljina prednjih i stražnjih drugih putujućih jedinica (22-25; 27, 28; 36b-39b; 60; 61, 62; 66) u lijevom i desnom smjeru postavljena da budu dulja nego duljina prvih putujućih jedinica (22-25; 27, 28; 36a-39a; 60) u lijevom i desnom smjeru.
The adenosine deaminase for use of claim 6 or 12, wherein the adenosine deaminase is conjugated to the polyethylene glycol via a urethane linkage. 
Adenozin-deaminaza, namijenjena upotrebi u skladu s patentnim zahtjevom 6 ili 12, naznačena time što je adenozin-deaminaza konjugirana s polietilen-glikolom uz pomoć uretanske spojnice.
■ A first hook-and-loop connecting element fixed to said first and/or second zone thereby providing a first hook-and-loop surfaced area; 
▪ prvi kuka-i-petlja spojni element (2) koji je učvršćen na navedenu drugu zonu i tako osigurava prvo kuka-i-petlja oplošje;
said C1 to C6 alkyl carbonyl compound is selected from the group consisting of acetaldehyde, acetone, glyoxylic acid, and gyloxylate; and/or 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni niži alkilkarbonilni spoj se bira iz skupine koju čine acetaldehid, aceton, glioksilna kiselina i giloksilat.
Another important constituent of the composite material is the polymerizable resin base which is described in detail under “Polymerizable resin base”. 
Sljedeći važan sastojak kompozitnog materijala je baza za smolu koja polimerizira, a koja je opisana detaljno pod "Baza za smolu koja polimerizira",
The powder is then heated in an oven with dry atmosphere for 2 hours with a ramp of 4 hours to the temperature of the crystal formation temperature (443° C. for this batch) of the amorphous zirconia powder. 
Prašak je zatim zagrijavan u peći sa suhom atmosferom kroz 2 sata s vremenom od 4 h za postizanje temperature tvorbe kristala (443 "C za ovaj uzorak) amorfnog praška cirkonijeva oksida.
a first active comprising the compound as defined in any of Claims 1 to 11 and a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. 
-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid; ili njegova farmaceutski prihvatljiva sol, te drugo djelatno sredstvo odabrano od sljedećih: osmotski agens, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminici, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvo i drugo djelatno sredstvo mogu biti u istom farmaceutskom sastavu ili u različitim farmaceutskim sastavima.
A combination for use according to embodiment 11, for use in the treatment of breast cancer, particularly triple negative breast cancer. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 9, naznačena time što je namijenjena upotrebi u liječenju raka dojke, osobito trostruko negativnog raka dojke.
The heteromolecular metal complex according to claim 1, wherein organic molecule A is a humic acid that has been treated with at least one of an acid and a phenolic group in a step subsequent to the formation of the heteromolecular complex. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u zahtjevima 1 do 7, naznačeni time što je molekula A huminska kiselina koja je bila tretirana sa kiselinom i/ili fenolnim skupinama u koraku koji je uslijedio nakon tvorbe heteronuklearnog kompleksa.
GnRH receptors in the pituitary gland mediate GnRH-stimulated LH release into the circulation. 
Receptori GnRH u hipofizi posreduju kod GnRH-om stimuliranog otpuštanja LH u krvotok.
During manufacture, the spout is often inserted inside the opening of the container before the container is filled. 
Općenito se kljun umetne unutra prije nego što se spremnik napuni.
A sealed container according to any of claims 11 to 13, wherein the lidding film is a multi-layer film comprising a seal layer and the seal layer comprises polypropylene (PP) and/or PE. 
Cc) osiguravanje višeslojnog filma poklopca koji sadrži sloj za spajanje i gdje sloj za spajanje sadrži polipropilen (PP) i/ili PE.
The pharmaceutical composition comprising a therapeutically effective amount of an angiotensin II receptor 1 (AT-1) antagonist for use as a medicament according to any one of claims 1 to 3, wherein the therapeutically effective amount of the angiotensin II receptor 1 (AT-1) antagonist is 0.01 to 5.0 mg/kg of body weight. 
Sartan za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se farmaceutski sastav primjenjuje na mački u terapeutski djelotvornoj količini koja dovodi do kumulativne intravenozne doze sartana od najmanje oko 0,025 mg po kilogramu tjelesne mase.
The antibody of claim 4, wherein the non-natural amino acid residue is substituted with a moiety selected from the group consisting of amino, carboxy, acetyl, hydrazino, hydrazido, semicarbazido, sulfanyl, azido, and alkynyl. 
Antitijelo iz bilo kojeg od prethodnih patentnih zahtjeva gdje spomenuti ne-prirodni aminokiselinski ostatak sadrži segment odabran iz grupe koja se sastoji od amino, karboksi, acetil, hidrazino, hidrazido, semikarbazido, sulfanil, azido i alkinil.
Exogenous antioxidants such as SOD and catalase have been shown to attenuate the leukocyte infiltration and tissue injury elicited by ischemia and reperfusion. 
Pokazalo se je da egzogeni antioksidanti, kao što su SOD 1 katalaza, ublažavaju infiltraciju leukocita 1 ozljedu tkiva izazvanu ishemijom i Teperfuzijom.
The organic-inorganic composite of claim 6, wherein the degree of substitution is selected in a range from 1.5 to 6 weight percent. 
Zidna gips ploča prema zahtjevu 9, naznačena time, da je stupanj supstitucije odabran iz raspona od 1,5 do 2,5 masenih postotaka hidroksipropila.
The method of claim 26, wherein the subject had an inadequate response to, contraindication to, or was intolerant to oral antibiotics for treatment of their HS. 
Anti-TNFa protutijelo za uporabu prema zahtjevu 14, naznačeno time, da je subjekt netolerantan na oralne antibiotike, ima kontraindikaciju za oralne antibiotike, ili ima neadekvatan odgovor na oralne antibiotike.
The method according to claim 1, characterized in that said membrane (13) is heated to approximately 100-150 °C for 10 seconds so as to be firmly coupled to the upper (12) by pressing at approximately 6 bars. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da navedena membrana (13) zagrijava se na oko 100 - 150 °C tijekom 10 sekundi kako bi se prešanjem s tlakom od oko 6 bara ostvario čvrsti spoj s gornjištem (12).
Alternatively, the matrix material or release retarding coating can take the form of an erodible polymer (e.g. a maleic anhydride polymer) which is substantially continuously eroded as the dosage form passes through the gastrointestinal tract. 
Altenativno, materijal matriksa ili prevlaka za usporavanje oslobađanja mogu biti u obliku erozivnog polimera (na primjer polimera maleinskog anhidrida) koji prolaskom dozimog oblika kroz probavni trakt gotovo stalno erodira.
A DNA detection kit comprising: at least one DNA molecule comprising at least 18 contiguous nucleotides homologous or complementary to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5 to function as a DNA primer or probe specific for corn event MON89034 and/or its progeny. 
Detekcijski DNA kit sadrži: minimalno jednu DNA molekulu koja se sastoji od najmanje 18 u nizu poredanih nukleotida homolognih ili komplementarnih SEQ ID NO: 3, SEQ ID NO: 4, ili SEQ ID NO: 5, da funkcionira kao DNA začetnica ili proba za biljku kukuruza oznake MON89034 i / ili njenih potomaka.
represents one or more substituents selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl; wherein alkyl, cycloalkyl and aryl groups can be optionally substituted by one or more substituents, selected from hydroxy, halogen, alkyl, alkoxy, trifluoromethoxy, trifluoromethyl, alkylsulfonyl; 
predstavlja jedan ili više supstituenata koji su odabrani od vodika, alkila, alkoksi, cikloalkila, arila; pri čemu alkilna, cikloalkilna i arilna skupina mogu proizvoljno biti supstituirane sa jednim ili više supstituenata koji su odabrani iz skupine koja sadrži hidroksi, halogen, alkil, alkoksi, trifluorometoksi, trifluorometil, alkilsulfonil;
The method of any preceding claim, wherein the solution of the preparing step and sample are mixed for at least 5 seconds and incubated at 21°C for at least 1 minute. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time što otopina iz koraka priprave i uzorak se miješaju najmanje 5 sekundi i inkubiraju pri 21 *€ najmanje 1 minutu.
the Crystal Violet is approximately 80% pure or greater; and the particle contrast agent composition further comprises an antimicrobial agent. 
Crystal Violet je približno 80% čista 1li više; i pripravak kontrastnog sredstva za čestice dodatno sadrži Proclin 300.
A method of immunization for reducing toxic damage caused by oligomeric forms of the amyloid-B protein in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a peptide as immunogen to raise an immune response in said mammal against toxic oligomeric forms of the amyloid-B protein, said peptide comprising: the amino acid sequence L-V-F-F-C(SEQ ID NO: 13) corresponding to amino acids 17 to 21 of SEQ ID NO: 4 and the amino acid sequence C-1-1-G-L-M-V (SEQ ID NO: 14) corresponding to amino acids 30 to 36 of SEQ ID NO: 4; exactly two cysteines corresponding to Cys21 and Cys30 in SEQ ID NO: 4; and exactly one disulfide bond, said exactly one disulfide bond is between said two cysteines corresponding to Cys21 and Cys30 in SEQ ID NO: 4, wherein said peptide is resistant towards fibrillogenesis. 
Amiloidni beta peptid koji sadrži sekvencu amino kiseline L-V-F-F-C koja odgovara amino kiselinama 17 do 21 iz SEQ ID NO:4 i sekvencu amino kiseline C-I-I-G-L-M-V koja odgovara amino kiselinama 30 do 36 iz SEQ ID NO:4, te navedeni amiloidni beta peptid nadalje sadrži disulfidnu vezu između cisteinskih ostataka koja odgovara amino kiselinama 21 i 30 iz SEQ ID NO:4, ili varijantu navedenog amiloidnog beta peptida naznačen time da su jedna, dvije, tri, četiri, ili pet amino kiselina zamijenjene s konzervativnom supstitucijom, da je izbrisana jedna, dvije, tri, četiri, ili pet amino kiselina, ili je umetnuta jedna, dvije, tri, četiri, ili pet amino kiselina, navedeni amiloidni beta peptid ili navedena varijanta navedenog amiloidnog beta peptida ima točno dva cisteina, te navedeni cisteini odgovaraju Cys21 i Cys30 iz SEQ ID NO:4.
drying the precipitate at a temperature ranging from room temperature to 40°C under a pressure ranging from ambient pressure to 0.001 Torr, for a duration of time ranging from 10 minutes to 1 day. The solid precipitate can be washed by the use of apolar solvent. 
sušenja dobivenog taloga na temperaturi u rasponu od sobne temperature do 40 *C pod tlakom koji se kreće između tlaka okoliša i vakuuma, u trajanju u rasponu od 5 minuta do 1 dan, gdje se talog prije sušenja može isprati nepolarnim otapalom.
The method of claim 16, wherein the impermeable film is fed in the same direction as the inner tubular member existing the resin bath to wrap the impregnated tubular member and seal the impermeable film. 
Postupak prema zahtjevu 8, naznačen time da se nepropusni film (66) uvodi u istome smjeru kao i unutarnji cjevasti element (45) koji izlazi iz kupke sa smolom radi omatanja cjevastog elementa (45) i brtvljenja nepropusnog filma (66).
The coated metal implant according to claims 1 or 2, wherein the UV light of step (b) is approximately 6 mW/cm2. 
Obloženi metalni implantat u skladu s patentnim zahtjevima 1 1li 2, pri čemu je UV svjetlo iz koraka (b) približno 6 mW/cm'".
crystallizing the potassium salt of Nor-UDCA or Bis-nor-UDCA; and optionally dissolving the potassium salt in a solvent and acidifying the solution to obtain pure UDCA or Bis-nor-UDCA. 
– kristaliziranja kalijeve soli Nor-UDCA; i – izbornog otapanja kalijeve soli u otapalu, te zakiseljavanje otopine kako bi se dobio čisti Nor-UDCA.
Thereafter heptane (62.8 kg) was added at a constant rate over 2 hours. 
Nakon toga je dodan heptan (62,8 kg) konstantnom stopom tijekom 2 sata.
The amorphous solid dispersion for use according to Claim 6, wherein the previous treatment for brain cancer is selected from surgery, conventional external radiation therapy, three-dimensional conformal radiation therapy, intensity modulated radiation therapy, stereotactic radiosurgery, fractionated stereotactic radiation therapy, proton radiation therapy, internal or implant radiation therapy, temozolomide, bevacizumab, carmustine, lomustine, procarbazine, vincristine, tumor treating fields therapy, everolimus, procarbazine, lomustine, cisplatin, carboplatin and methotrexate or mixtures thereof. 
Disperzija amorfne krutine, namijenjena upotrebi u skladu s patentnim zahtjevom 6, naznačena time što se prethodno liječenje raka na mozgu bira između kirurškog zahvata, konvencionalne vanjske radioterapije, trodimenzijske konformacijske radioterapije, radioterapije moduliranog intenziteta, stereotaktičkog radiokirurškog zahvata, frakcionirane stereotaktičke radioterapije, protonske radioterapije, unutarnje ili implancijske radioterapije, temozolomida, bevacizumaba, karmustina, lomustina, prokarbazina, vinkristina, terapije poljima za liječenje tumora, everolimusa, prokarbazina, lomustina, cisplatina, karboplatina i metotreksata, ili njihovih kombinacija.
in which R1A and R3 are each as defined above, reacting the compound of formula (IV) in an inert solvent, in the presence of a suitable base, with a compound of the formula (V) 
(IV) gdje R'" i R* su svaki kako je gore definirano, ovo nakon toga reagira u inertnom otapalu, u prisutnosti odgovarajuće baze, sa spojem s formulom (V) X!'.R?
The wind system of claim 33, wherein the recovering system comprises at least one disappearing guiding system to facilitate landing of the kites onto the container with hinged cover opened as a platform, the disappearing guiding system being preferably placed next to the container with hinged cover, the disappearing guiding system is composed of at least one pair of rods placed on the sides of the container with hinged cover, the disappearing guiding system being preferably controlled by the smart control system. 
Vjetreni sustav (1) prema zahtjevu 33, naznačen time da spomenuti sustav za vraćanje zmajeva (8) uključuje barem jedan uvlačivi sustav za vođenje čime se omogućava slijetanje spomenutih zmajeva (2) na spomenuti spremnik s poklopcem sa šarkama koji je otvoren kao platforma, pri čemu je poželjno da taj uvlačivi sustav za vođenje bude postavljen pored spomenutog spremnika s poklopcem sa šarkama, da je taj sustav za vođenje sastavljen od barem jednog para šipki smještenih na stranicama spomenutog spremnika s poklopcem sa šarkama i da tim uvlačivim sustavom za vođenje upravlja spomenuti pametni kontrolni sustav.
wherein the administering results in a reduction in the diarrhea, constipation, or diarrhea and constipation in the subject. 
u postupku liječenja dijareje pri čemu subjekt ima dijareju bez konstipacije; i/ili
is hydrogen, chloro, or fluoro; provided that at least one of R2 and R3 is hydrogen; 
R* je vodik, klor ili fluor; uz uvjet da najmanje jedan od R? i R? je vodik; i
The siRNA according to claim 1, which is selected from the following (a) to (s): 
siRNA koja ima punu dužinu od 21 do 23 nukleotida, naznačena time, da je odabrana od sljedećih (a) do (o):
The use according to any one of claims 12 to 16, characterized in that the reuterin is added to the aqueous preparation in an amount based on the weight of water of from about 100 to 5000 ppm, preferably from about 200 to 2000 ppm, more preferably from about 450 to 1000 ppm, e.g. 
Uporaba prema bilo kojem od zahtjeva 12 do 16, naznačena time da se reuterin dodaje u vodeni pripravak u količini zasnovanoj na masi vode od oko 100 do 5000 ppm, poželjno od oko 200 do 2000 ppm, još poželjnije od oko 450 do 1000 ppm, npr.
HO-R1 (IV) wherein R1 is defined above, in the presence of a condensing agent to allow esterification. 
HO-R (IV) gdje R je određen gore, u prisutnosti kondenzatora da se omogući esterifikacija.
The method of claim 8 wherein the step of forming and translating the FRCs includes energizing a set of coils of individual ones of a plurality of strap assemblies wrapped around the elongate tube of the first and second formation sections, wherein the formation systems comprise a plurality of power and control units coupled to individual ones of the plurality of strap assemblies. 
Postupak prema zahtjevu 1, 4 do 5 i 7 do 8, naznačen time, da faza formiranja i translatiranja FRC-konfiguracija uključuje uvođenje energije u komplet zavojnica od pojedinačnih od mnoštva rasponskih sklopova (230) koji su omotani oko izdužene cijevi od prvog i drugog tvorbenog dijela, gdje tvorbeni sustavi obuhvaćaju mnoštvo pogonskih i upravljačkih jedinica (220) spojenih na pojedinačne od mnoštva rasponskih sklopova.
reducing EPA ethyl ester (1) having a purity of about 97% or about 98%: in the presence of lithium aluminum hydride in tetrahydrofuran at a temperature ranging from 0°C to 15°C to its corresponding alcohol (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol (2) 
= = ON u prisutnosti litijevog aluminijevog hidrida u tetrahidrofuranu kod temperature u rasponu od 0*C do 15*C u njegov odgovarajući alkohol (52,82,112,147,177)-ikoza-5,8,11,14,17-pentaen-1-ol (2) m
The container means of claim 27 wherein said container is made of glass, metals or polymers. 
Spremnik u skladu s patentnim zahtjevom 27, naznačena time što je navedeni spremnik načinjen od stakla, metala ili polimera.
R9, R10, and R11 are hydrogen or lower alkyl optionally substituted by substituent group A, and 
R*, R'",i R', su vodik ili niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, i
A method of inhibiting the replication of influenza viruses in a biological sample or patient, comprising the step of administering to said biological sample or patient an effective amount of a compound as described in any one of clauses 1-38. 
Postupak za inhibiciju replikacije virusa gripe u in vitro biološkom uzorku koji sadrži korak primjene na navedeni 10 biološki uzorak efikasne količine spoja formule: ili njegove farmaceutski prihvatljive soli.
The composition of claim 1, wherein at the most 5% w/w of the total amount of the dimethylfumarate contained in the composition is released within the first 2 hours after start of the test. The composition of claims 1 or 2, wherein the dissolution profile is measured using the basket method or the paddle method at 100 rpm. 
unutar prva 3 sata nakon početka ispitivanja oslobodi se najviše 70% w/w ukupne količine dimetilfumarata sadržanog u sastavu, i unutar prva 4 sata nakon početka ispitivanja oslobodi se najviše 92% w/w ukupne količine dimetilfumarata.
In an embodiment of the invention said composition is a liquid formulation or a solid formulation, wherein said solid formulation is selected from the group consisting of tablets, sucking tablets, sweets, chewing tablets, chewing gums, capsules, sachets, powders, granules, coated particles and coated tablets, enterocoated tablets and capsules, and melting strips and films, and said liquid formulation is selected from the group consisting of oral solutions, suspensions, emulsions and syrups. 
Smjesa za uporabu prema bilo kojem od zahtjeva 1-3, gdje je ta smjesa u tekućem obliku ili čvrstom obliku. Smjesa za uporabu prema zahtjevu 4, gdje se čvrsti oblik izabire iz grupe koja obuhvaća tablete, tablete za cuclanje, slatkiše, tablete za žvakanje, žvakaće gume, kapsule, vrećice, praške, granule, obložene čestice i obložene tablete, tablete i kapsule s gastro-rezistentnom ovojnicom, te trake i filmove za otapanje.
An oral pharmaceutical tablet according to claim 1, wherein the hydrophilic matrix is present from 1% to 15%, preferably from 2% to 10%, and more preferably from 3% to 5% by weight based on the total weight of the tablet. 
Oralna farmaceutska tableta u skladu s patentnim zahtjevom 1, naznačena time što hidrofilni matriks čini od 1% do 15%o, po mogućnosti od 2% do 10%o, a poželjnije od 3%> do 5%>, težinski, prema ukupnoj težini tablete.
The residue is washed with saturated sodium hydrogen carbonate solution and this aqueous portion is extracted with DCM (3 x 10 ml). 
Ostatak se ispere sa zasićenom otopinom natrijevog hidrogen karbonata i taj vodeni dio se ekstrahira s DCM-om (3 x 10 ml).
The composition of any one of the previous claims, wherein the C1 esterase inhibitor has an amino acid sequence at least 90%, 95%, 98%, 99% or 100% identical to the human C1 esterase inhibitor amino acid sequence of Figure 1. The composition of any one of the previous claims, wherein the C1 esterase inhibitor is present at about 500 U/ml. 
Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da je najmanje jedan inhibitor C1 esteraze izoliran ili pročišćen iz ljudske plazme ili je dobiven pomoću tehnika rekombinacije, i/ili pri čemu inhibitor C1 esteraze ima sekvencu amino kiselina 90%, 95%, 98%, 99% ili 100% identičnu s ljudskom sekvencom amino kiselina inhibitora C1 esteraze na slici 1.
a heavy chain variable domain consisting of the sequence of amino acids set forth in SEQ ID NO: 68 and a light chain variable domain consisting of the sequence of amino acids set forth in SEQ ID NO: 70; or a variable heavy chain consisting of a sequence of amino acids that has a sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to the heavy chain set forth in SEQ ID NO: 68 and a variable light chain consisting of a sequence of amino acids that has a sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% to the light chain set forth in SEQ ID NO: 70; and 
teški lanac varijabilne domene koji sadrži sekvencu aminokiselina navedenu u SEQ ID NO: 68 i laki lanac varijabilne domene koji sadrži sekvencu aminokiselina navedenu u SEQ ID NO: 70; ili varijabilni teški lanac koji sadrži sekvencu aminokiselina koja ima identitet sekvence od barem 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 % ili 99 % prema teškom lancu navedenom u SEQ ID NO: 68 i varijabilni laki lanac koji sadrži sekvencu aminokiselina koja ima identitet sekvence od barem 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % prema lakom lancu navedenom u SEQ ID NO: 70; i